During the recent session, 10x Genomics Inc (NASDAQ:TXG)’s traded shares were 1.53 million, with the beta value of the company hitting 1.90. At the last check today, the stock’s price was $11.56, reflecting an intraday loss of -3.63% or -$0.44. The 52-week high for the TXG share is $51.22, that puts it down -343.08 from that peak though still a striking 0.09% gain since the share price plummeted to a 52-week low of $11.55. The company’s market capitalization is $1.40B, and the average intraday trading volume over the past 10 days was 3.01 million shares, and the average trade volume was 2.08 million shares over the past three months.
10x Genomics Inc (TXG) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 2.61. TXG has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.29.
10x Genomics Inc (NASDAQ:TXG) trade information
10x Genomics Inc (TXG) registered a -3.63% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.63% in intraday trading to $11.56, hitting a weekly high. The stock’s 5-day price performance is -21.06%, and it has moved by -25.10% in 30 days. Based on these gigs, the overall price performance for the year is -76.45%. The short interest in 10x Genomics Inc (NASDAQ:TXG) is 8.42 million shares and it means that shorts have 4.41 day(s) to cover.
The consensus price target of analysts on Wall Street is $25, which implies an increase of 53.76% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $24 and $46 respectively. As a result, TXG is trading at a discount of -297.92% off the target high and -107.61% off the low.
10x Genomics Inc (TXG) estimates and forecasts
In the rating firms’ projections, revenue will increase 0.53% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 134.72M as predicted by 13 analyst(s). Meanwhile, a consensus of 13 analyst(s) estimates revenue growth to 146.89M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 141.01M and 153.1M respectively. In this case, analysts expect current quarter sales to shrink by -4.46% and then drop by -4.06% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -13.04%. While earnings are projected to return 5.28% in 2025, the next five years will return 16.22% per annum.
TXG Dividends
10x Genomics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
The next largest institutional holding, with 10.19 million shares, is of VANGUARD GROUP INC’s that is approximately 8.5341% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $198.18 million.
Also, the Mutual Funds coming in first place with the largest holdings of 10x Genomics Inc (TXG) shares are ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund. Data provided on Dec 31, 2024 indicates that ARK ETF Tr-ARK Innovation ETF owns about 8.25 shares. This amounts to just over 7.71 percent of the company’s overall shares, with a $95.88 million market value. The same data shows that the other fund manager holds slightly less at 3.25, or about 3.04% of the stock, which is worth about $37.74 million.
